Digest Network Come funziona
Network
/
Società
F.
Non verificato

F. Hoffmann-La Roche Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaPubblicità/Marketing/Media/Comunicazione

108 comunicati stampa

Guarda tutti i comunicati
10/12/2025
Farmaceutica
Annunci Economici
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/12/2025
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/12/2025
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/12/2025
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/12/2025
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/12/2025
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
01/12/2025
Farmaceutica
Annunci Economici
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/11/2025
Farmaceutica
Annunci Economici
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
17/11/2025
Farmaceutica
Annunci Economici
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
09/11/2025
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0